WuXi AppTec Co Ltd (2359.HK): More Capex Deployment into Preclinical Research Capacity

Morgan Stanley updated WuXi AppTec (2359.HK), maintaining Overweight with a HK$220 price target, implying ~12% upside from the HK$196.50 close on Oct 20, 2026. Last week's construction kickoff at Changzhou STA entails ~Rmb10bn deployed over the next three years, with tonnage allocated across multiple therapeutic areas including diabetes, oncology, cardiovascular and antiviral. API Intelligence also reported an expansion kickoff at WuXi's Suzhou LifeBay site, dedicated to preclinical research, covering 16,775 sqm (Phase 2) with Rmb1,060mn to be deployed over the next 10 months;